- FUJIFILM Biotechnologies was named a winner in the “Most Innovative CDMO (Biologics)” category at the 2026 CDMO Leadership Awards.
- The recognition is based on sponsor feedback and highlights the company’s investments in science, process development, and new technologies.
FUJIFILM Biotechnologies has been named a winner in the “Most Innovative CDMO (Biologics)” category at the 2026 CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect. The awards were announced during DCAT Week, held on March 25 in New York City.
The CDMO Leadership Awards are based on direct feedback from biopharma sponsors who have worked with contract manufacturing organizations over the past 18 to 24 months. The evaluation considers performance across key criteria, with recognition granted to companies meeting defined qualification thresholds within each category.
The company stated that the award reflects its ongoing investments in science, analytics, and process development to support biologics, vaccines, and advanced therapies from early development through commercialization. These efforts include the development of new technology platforms aimed at improving manufacturing processes.
“As part of Fujifilm’s 90-year heritage in healthcare innovation, our company continues to invest in science, analytics, and process development to support biologics, vaccines, and advanced therapies from early development through commercialization.”
Bernie Clark, Vice President of Global Marketing at FUJIFILM Biotechnologies
FUJIFILM Biotechnologies also highlighted the recent launch of ShunzymeX™, a technology platform designed to simplify the purification of complex biologics using a novel protease. The company attributed the recognition to its continued collaboration with industry and academic partners, as well as its focus on advancing drug development and manufacturing capabilities.
